Patents Assigned to Institut Gustave Roussy
  • Publication number: 20240010990
    Abstract: The present invention concerns a novel in vitro assay for determining the invasive ability of brain tumour cells, in particular brain tumour stem cells. This new assay, called 3D invasion assay, is based on the analysis and comparison of the area of neurospheres grown in vitro into a Matrigel extracellular-like matrix. The invention also concerns the use of said assay for diagnosing metastatic brain tumour in subjects, for determining its prognosis, as well as for the monitoring, for the stratification, for identifying subjects at risk of metastasis, and/or predicting the metastasis-associated risk in subjects diagnosed with brain tumour.
    Type: Application
    Filed: September 14, 2021
    Publication date: January 11, 2024
    Applicant: Institut Gustave Roussy
    Inventors: David CASTEL, Marie Anne DEBILY, Jacques GRILL, Marco BRUSHI
  • Publication number: 20230302031
    Abstract: The inventors herein show that purinergic receptors regulate the conversion of macrophage pro-inflammatory reprogramming into anti-inflammatory phenotype in patients suffering from COVID-19 disease. Moreover, they show that P2Y receptor agonists repress NLRP3 inflammasome-dependent IL-1b secretion, but also impair the replication and the cytopathogenic effects of SARS-CoV-2. These results therefore suggest that some purinergic receptors agonists can treat acute lung injury and respiratory disease that are associated with SARS-CoV-2 infection. In addition, their results show that antagonists of the purinergic receptors P2X impair the replication of said virus. The present invention therefore proposes to use purinergic receptors modulators and NLR3-P2Y2R immune checkpoint modulators to treat patients suffering from a virus-induced acute respiratory distress syndrome.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 28, 2023
    Applicant: Institut Gustave-Roussy
    Inventors: Jean-Luc PERFETTINI, Deborah LECUYER, Desiree TANNOUS, Awatef ALLOUCH, Oliver DELELIS, Frederic SUBRA
  • Patent number: 11730732
    Abstract: A pharmaceutical liquid suspension comprising: temozolomide or a salt thereof; at least one agent controlling the solid state of temozolomide in suspension; a pharmaceutically acceptable liquid vehicle; and optionally at least one acid in a quantity so that the pH of the composition is below 5; or a powder blend for reconstituting said suspension, is provided.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: August 22, 2023
    Assignees: Orphelia Pharma, Institut Gustave Roussy
    Inventors: Maxime Annereau, Jérémy Bastid, Hugues Bienayme, François Lemare, Mathieu Schmitt, Lionel Tortolano, Samuel Abbou
  • Patent number: 11732303
    Abstract: The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that proposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF), secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL, and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis, a secondary MDS or an AML.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: August 22, 2023
    Assignee: Institut Gustave-Roussy
    Inventors: Christine Bellane-Chantelot, Isabelle Plo, William Vainchenker, Cécile Saint-Martin, Antonio D Di Stefano, Joseph Saliba
  • Publication number: 20230203005
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Application
    Filed: March 6, 2023
    Publication date: June 29, 2023
    Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad ALAMI, Olivier PROVOT, Abdallah HAMZE, Ilhem KHELIFI, Timothée NARET, Sébastien APCHER, Romain DARRIGRAND
  • Patent number: 11684640
    Abstract: The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: June 27, 2023
    Assignees: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, UNIVERSITE PARIS-SACLAY, Insitut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE)
    Inventors: Laurence Zitvogel, Bertrand Routy, Emmanuelle Le Chatelier
  • Patent number: 11634405
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: April 25, 2023
    Assignees: UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad Alami, Olivier Provot, Abdallah Hamze, Ilhem Khelifi, Timothée Naret, Sébastien Apcher, Romain Darrigrand
  • Patent number: 11603568
    Abstract: Although tumor-associated macrophages have been extensively studied in the control of response to radiotherapy, the molecular mechanisms involved in the ionizing radiation-mediated activation of macrophages remain elusive. Here the present inventors show that ionizing radiation induces the expression of interferon-regulatory factor 5 (IRF5) promoting thus macrophage activation toward a pro-inflammatory phenotype. They reveal that the activation of the Ataxia telangiectasia mutated (ATM) kinase is required for ionizing radiation-elicited macrophage activation, but also for macrophage reprogramming after treatments with ?-interferon, lipopolysaccharide or chemotherapeutic agent (such as cis-platin), underscoring the fact that the kinase ATM plays a central role during macrophage phenotypic switching toward a proinflammatory phenotype. They further demonstrate that NADPH oxidase 2 (NOX2)-dependent ROS production is upstream to ATM activation and is essential during this process.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 14, 2023
    Assignee: Institut Gustave Roussy
    Inventors: Jean-Luc Perfettini, Eric Deutsch, Awatef Allouch
  • Publication number: 20230000801
    Abstract: A freeze-dried powder for preparing a thermogel including: from 1% to 35% of 2-[(3-aminopropyl)amino]ethanethiol or one of its pharmaceutically acceptable salt; from 40% to 85% of one or more poloxamer; and from 0.1% to 20% of one or more carbohydrate compound.
    Type: Application
    Filed: November 24, 2020
    Publication date: January 5, 2023
    Applicants: CLEVEXEL PHARMA, INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SACLAY
    Inventors: Denis BRICOUT, Xiuping WANG-ZHANG, Eric DEUTSCH, Céline CLEMENSON
  • Patent number: 11517575
    Abstract: The present invention is drawn to the use of Minaprine dihydrochloride and analogs thereof, for reducing tumor growth when administered to a patient suffering from cancer.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: December 6, 2022
    Assignee: Institut Gustave Roussy
    Inventors: Jean Luc Perfettini, Eric Deutsch, Catherine Brenner, Jean-Christophe Cintrat, Frederic Taran
  • Patent number: 11471463
    Abstract: The present invention is drawn to the use of the compounds highlighted in Tables 1 & 2 and analogs thereof, for enhancing IR-mediated cellular cannibalism in cancer cells. Said compounds are herein called “enhancers of IR-mediated cellular cannibalism”. They can be used to enhance tumor immunogenicity and/or to induce a significant protective anticancer immune response in subjects that will receive or that have received a radiotherapy treatment. In other words, said compounds can be used to potentiate a radiotherapy treatment in a subject in need thereof. Said compounds are preferably chosen in the group consisting of: Mebhydroline 1,5-napthalene disulfonate salt, Flurbiprofen, Minaprine dihydrochloride, Myricetin, Digoxin, Digitoxin, Lanatoside, LOPA87, VP331, RN-1-026, SG6163F, VP450, and VP43.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: October 18, 2022
    Assignee: Institut Gustave Roussy
    Inventors: Jean Luc Perfettini, Eric Deutsch, Catherine Brenner, Jean-Christophe Cintrat, Frederic Taran
  • Patent number: 11466327
    Abstract: The present invention relates to the use of the value of the expression of at least one gene selected from the group comprising: GBP 1 gene, HLF gene, CXCL13 gene and SULT1E1 gene, for the estimation of prognosis of distant relapse-free survival or overall survival of a patient with triple negative breast cancer (TNBC) having received a neoadjuvant chemotherapy (NACT).
    Type: Grant
    Filed: July 3, 2017
    Date of Patent: October 11, 2022
    Assignees: ISTITUTO EUROPEO DI ONCOLOGIA (IEO), INSTITUT GUSTAVE ROUSSY
    Inventors: Michiels Stefan, Mohamed Amine Bayar, Fabrice Andre, Carmen Criscitiello, Giuseppe Curigliano
  • Publication number: 20220257709
    Abstract: Identification of effective targets alleviating the programmed cell removal (PrCR) of tumor cells by macrophages is of very high interest. The present inventors have identified that the cyclin-dependent kinase inhibitor p21 protein is a strong regulator of the macrophage-mediated PrCR. Also, they showed that the adoptive transfer of p21 overexpressing monocytes induces macrophage PrCR and transition from an anti-inflammatory to a pro-inflammatory phenotype in vivo, delays cancer progression and increases significantly the overall survival of mice engrafted with cancer cells. The present invention therefore concerns therapeutic compositions comprising monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, especially leukemia.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 18, 2022
    Applicant: Institut Gustave-Roussy
    Inventors: Jean-Luc PERFETTINI, Awatef ALLOUCH, Eric DEUTSCH
  • Patent number: 11401312
    Abstract: The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: August 2, 2022
    Assignees: Cytune Pharma, Institut Gustave Roussy (IGR)
    Inventors: David Bechard, Nathalie Chaput, Melanie Desbois
  • Patent number: 11344586
    Abstract: The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: May 31, 2022
    Assignees: INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
    Inventors: Laurence Zitvogel, Ivo Gomperts Boneca, Patricia Lepage, Sophie Viaud, Romain Daillere
  • Patent number: 11293066
    Abstract: The present invention relates to a method for assessing the response to PD-1/PDL-1 targeting drugs based on the differential expression levels of BINP3 and GBE1.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: April 5, 2022
    Assignee: INSTITUT GUSTAVE ROUSSY
    Inventors: Salem Chouaib, Stéphanie Buart
  • Publication number: 20220042016
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Application
    Filed: September 29, 2021
    Publication date: February 10, 2022
    Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUD
    Inventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
  • Patent number: 11203788
    Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: December 21, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, UNIVERSITE PIERRE ET MARIE CURIE, UNIVERSITE PARIS-SUD
    Inventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
  • Patent number: 11179449
    Abstract: The invention relates to combinations of peptides carrying T-cell epitopes of the antigen preprocalcitonin, presented by the MHC. These peptides can be used in anti-tumour immunotherapy.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: November 23, 2021
    Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale, Université Paris-Saclay
    Inventors: Fathia Mami-Chouaib, Aurélie Durgeau
  • Patent number: 11162100
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: November 2, 2021
    Assignees: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, UNIVERSITE PARIS-SUD
    Inventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall